Enhanced patient-specific intestine-on-a-chip model | Mimetas

Enhanced patient-specific intestine-on-a-chip model

Enhanced patient-specific intestine-on-a-chip model

Millions of people worldwide experience pain and stress due to intestinal inflammation, emphasizing the need for the development of diagnostic strategies and therapeutic interventions. However, without suitable research models for studying intestinal functions, progress in research and drug discovery is difficult. The OrganoPlate® was developed to fill this gap and provides a robust, flexible platform that is amenable to drug screening. Recent adaptations1,2 of a previously established intestine-on-a-chip model3 have paved the way for new opportunities in high-throughput drug discovery and research related to intestinal inflammation.

The OrganoPlate® is a microfluidic platform that facilitates research across a wide range of physiological processes, including hepatic, renal, and intestinal function. A recent publication by scientists at MIMETAS and international collaborators at the University of Sheffield describing the Direct On-Chip Differentiation of Intestinal Tubules from Induced Pluripotent Stem Cells (iPSCs) demonstrates improvements on the existing model, and represents significant progress towards a versatile, more complex platform for future drug discovery efforts.

The need for advanced in vitro models

Inflammatory bowel disease (IBD) is a collective term used to describe a range of disorders involving intestinal inflammation, and is estimated to affect more than 6.8 million people globally4,5. The individual burden of IBD can be significant; those affected commonly experience chronic pain and stress, with symptoms ranging from mild to highly debilitating. Despite the clear need for preventative and therapeutic agents, such solutions are lacking – largely because the underlying mechanisms of intestinal inflammation remain poorly understood. In order to facilitate studies designed to explore intestinal inflammation and potential therapies, there is a need for research models that are:

  • Robust and reproducible
  • Amenable to screening
  • Sufficiently complex
  • Flexible
  • Personalized


In recent years, major efforts have been directed towards the development of in vitro models of intestinal physiology: three-dimensional cultures, organoids, and microfluidics. Each of these provide important biologically relevant features, yet they are typically not suited for high-throughput screening. The OrganoPlate® platform helps to fill this gap as it allows for the culturing of leak-tight, polarized epithelial gut tubules on a standardized platform that is compatible with high-throughput screening equipment6. These features make it a valuable tool in drug discovery settings, as key aspects of IBD pathogenesis,e.g. increased cytokine production and the loss of barrier integrity can be recapitulated6.

As a result, the OrganoPlate® has been selected by several pharmaceutical companies to support studies into the mechanisms behind IBD, and diarrhea toxicity observed during a Phase 1 clinical trial6,7. As that model was based on a single cell line, however, MIMETAS saw room for improvement, and recognized the need to expand the OrganoPlate®’s capacity for mimicking biological complexity. 

Towards patient-specific organoid tubules for personalized medicine approaches

There is no “one-size-fits-all” approach to the treatment of IBD, which is unsurprising given the substantial variation in phenotype and disease course that exists across individuals8. As with many other conditions, a more personalized approach to the diagnosis and treatment of intestinal inflammation could improve clinical outcomes, as decisions could be based on a deeper understanding of an individual’s specific disease mechanisms. Such an approach has been made possible by technological advances, such as those in genomics and proteomics, but its potential is yet to be realized. For personalized medicine to become a reality, in vitro patient-specific models are needed to mimic intestinal diseases.

With this goal in mind, our scientists at MIMETAS and our collaborators at the University of Sheffield developed a protocol for the directed differentiation of iPSCs into three-dimensional gut-like tubules in the OrganoPlate®. An assessment of stem cell and adult intestinal gene expression markers revealed stepwise differentiation through definitive endoderm, hindgut and intestinal stages, with barrier function and apical-basal polarity established over the course of two weeks. The iPSC-derived tubules were challenged with a cytokine cocktail to determine their susceptibility to inflammatory stimuli. Following exposure to tumour necrosis factor-α, interleukin-1β and interferon-γ, an increase in gene expression of IL-6, IL-8 and CCL20 was observed in the tubules, indicating a significant inflammatory response.

Completed in only 14 days, the protocol provides an efficient approach for personalized intestinal model development, without the need for an intermediary organoid step. Unlike organoid models, this approach enables straightforward access to both the apical and basal sides of the epithelium – a crucial consideration for drug development applications.


  1. Gijzen L, Marescotti D, Raineri E, et al. An Intestine-on-a-Chip Model of Plug-and-Play Modularity to Study Inflammatory Processes. SLAS TECHNOLOGY: Translating Life Sciences Innovation. Published online June 24, 2020:247263032092499. doi:10.1177/2472630320924999
  2. Naumovska E, Aalderink G, Wong Valencia C, et al. Direct On-Chip Differentiation of Intestinal Tubules from Induced Pluripotent Stem Cells. International Journal of Molecular Sciences. 2020;21(14):4964. doi:10.3390/ijms21144964
  3. Trietsch SJ, Naumovska E, Kurek D, et al. Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes. Nature Communications. 2017;8(1). doi:10.1038/s41467-017-00259-3
  4. Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(1):17-30. doi:10.1016/s2468-1253(19)30333-4
  5. Jairath V, Feagan BG. Global burden of inflammatory bowel disease. The Lancet Gastroenterology & Hepatology. 2020;5(1):2-3. doi:10.1016/s2468-1253(19)30358-9
  6. Beaurivage C, Naumovska E, Chang Y, et al. Development of a Gut-on-a-Chip Model for High Throughput Disease Modeling and Drug Discovery. International Journal of Molecular Sciences. 2019;20(22):5661. doi:10.3390/ijms20225661
  7. Moisan A, Michielin F, Jacob W, et al. Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy. Molecular Cancer Therapeutics. 2018;17(7):1464-1474. doi:10.1158/1535-7163.mct-17-1268
  8. Ashton JJ, Mossotto E, Ennis S, Beattie RM. Personalising medicine in inflammatory bowel disease—current and future perspectives. Translational Pediatrics. 2019;8(1):56-69. doi:10.21037/tp.2018.12.03
Top 5: